2024

1. A Qualitative Tool to Guide in the Interpretation of the Numerical Rating Scale for Pruritus Intensity in Patients with Atopic Dermatitis

   Acta Dermato-Venereologica, Vol. 104

2. Avatrombopag in immune thrombocytopenia: A real-world study of the Spanish ITP Group (GEPTI)

   American Journal of Hematology

3. Clinical characteristics and impact on patient-reported outcomes and quality of life of people with ambulatory secondary progressive multiple sclerosis: Discover study

   Multiple Sclerosis and Related Disorders, Vol. 90

4. Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance

   Journal of Clinical Oncology, Vol. 42, Núm. 27, pp. 3247-3256

5. Development and Validation of a Scoring System to Predict Response to Obeticholic Acid in Primary Biliary Cholangitis

   Clinical Gastroenterology and Hepatology, Vol. 22, Núm. 10, pp. 2062-2074.e11

6. Effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in HIV late presenters

   International Journal of Antimicrobial Agents, Vol. 63, Núm. 1

7. Fostamatinib effectiveness and safety for immune thrombocytopenia in clinical practice

   Blood, Vol. 144, Núm. 6, pp. 646-656

8. Identification of patient-reported outcomes measures (PROMs) and patient-reported experiences measures (PREMs) in Gaucher disease in Spain

   Medicina Clinica, Vol. 163, Núm. 9, pp. 449-457

9. Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease

   Annals of Hematology

10. Impact of somatic gene mutations on the risk of thrombosis in myelofibrosis

    Leukemia

11. Integrating AIPSS-MF and molecular predictors: A comparative analysis of prognostic models for myelofibrosis

    HemaSphere

12. Integrative clinical, hormonal, and molecular data associate with invasiveness in acromegaly: REMAH study

    European Journal of Endocrinology, Vol. 190, Núm. 6, pp. 421-433

13. Longitudinal outcomes of obeticholic acid therapy in ursodiol-nonresponsive primary biliary cholangitis: Stratifying the impact of add-on fibrates in real-world practice

    Alimentary Pharmacology and Therapeutics, Vol. 59, Núm. 12, pp. 1604-1615

14. Low penetrance of frequent ATP7B mutations explains the low prevalence of Wilson disease. Lessons from real-life registries.

    Digestive and Liver Disease

15. Measurable residual disease by mass spectrometry and next-generation flow to assess treatment response in myeloma

    Blood

16. Porto-sinusoidal vascular liver disorder with portal hypertension: Natural history and long-term outcome

    Journal of Hepatology

17. Predictive factors for decompensating events in patients with cirrhosis with primary biliary cholangitis under different lines of therapy

    Hepatology (Baltimore, Md.), Vol. 80, Núm. 4, pp. 791-806

18. Prognostic impact of vasopressor test in transcatheter edge-to-edge repair of secondary mitral regurgitation: The PETIT study

    Catheterization and Cardiovascular Interventions, Vol. 104, Núm. 2, pp. 378-389

19. Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir

    Alimentary Pharmacology and Therapeutics, Vol. 60, Núm. 2, pp. 201-211

20. Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection

    Haematologica, Vol. 109, Núm. 6, pp. 1909-1917